m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer

Liang, Yen Nan; Cen, Junjie; Yao, Haohua; Lin, Haishan; Liang, Hui; Wang, Zhu; Deng, Qing; Cao, Jianping; Huang, Yong; Wei, Jinhuan; Luo, Junhang; Chen, Wei; Chen, Zhenhua

doi:10.1186/s12967-022-03711-1

Cited by 29 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several prognostic models about bladder cancer have been explored, and they classified bladder cancer with pyroptosis-related genes, ferroptosis-related genes, and neutrophil-related genes or m6A-immune-related lncRNA [ 35 – 38 ]. But our prognostic model is based on necroptosis-related genes in bladder cancer, and to predict the prognosis and treatment of bladder cancer.…”

Section: Discussionmentioning

confidence: 99%

A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer

et al. 2023

View full text Add to dashboard Cite

Bladder cancer, one of the most prevalent malignant cancers, has high rate of recurrence and metastasis. Owing to genomic instability and high-level heterogeneity of bladder cancer, chemotherapy and immunotherapy drugs sensitivity and lack of prognostic markers, the prognosis of bladder cancer is unclear. Necroptosis is a programmed modality of necrotic cell death in a caspase-independent form. Despite the fact that necroptosis plays a critical role in tumor growth, cancer metastasis, and cancer patient prognosis, necroptosis-related gene sets have rarely been studied in bladder cancer. As a result, the development of new necroptosis-related prognostic indicators for bladder cancer patients is critical. Herein, we assessed the necroptosis landscape of bladder cancer patients from The Cancer Genome Atlas database and classified them into two unique necroptosis-related patterns, using the consensus clustering. Then, using five prognosis-related genes, we constructed a prognostic model (risk score), which contained 5 genes (ANXA1, DOK7, FKBP10, MAP1B and SPOCD1). And a nomogram model was also developed to offer the clinic with a more useful prognostic indicator. We found that risk score was significantly associated with clinicopathological characteristics, TIME, and tumor mutation burden in patients with bladder cancer. Moreover, risk score was a valid guide for immunotherapy, chemotherapy, and targeted drugs. In our study, DOK7 was chosen to further verify our prognosis model, and functional assays indicated that knockdown the expression of DOK7 could prompt bladder cancer proliferation and migration. Our work demonstrated the potential role of prognostic model based on necroptosis genes in the prognosis, immune landscape and response efficacy of immunotherapy of bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Immunotherapy is an important for BLCA patients. Thus immune cell in ltration and immune-related genes had gained much research 26,27 .…”

Section: Discussionmentioning

confidence: 99%

Identification of hypoxia- and immune- based prognostic signature and validation of TFRC as a potential biomarker and therapeutic target in bladder cancer

Tang,

Wang,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Bladder cancer is a common malignancy of the urinary system, and the survival rate and recurrence rate of patients with muscular aggressive (MIBC) bladder cancer are not ideal. Hypoxia is a pathological process in which cells acquire special characteristics to adapt to anoxic environment, which can directly affect the proliferation, invasion and immune response of bladder cancer cells. Understanding the exact effects of hypoxia and immune-related genes in BLCA is helpful for early assessment of the prognosis of BLCA. However, the prognostic model of BLCA based on hypoxia and immune-related genes has not been reported. Purpose Hypoxia and immune cell have important role in the prognosis of bladder cancer (BLCA). The aim of this study was to investigate whether hypoxia and immune related genes could be a novel tools to predict the overall survival and immunotherapy of BLCA patients. Methods Firstly, we downloaded transcriptomic data and clinical information of BLCA patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. A combined hypoxia and immune signature was then constructed on the basis of the training cohort via least absolute shrinkage and selection operator (LASSO) analysis and validated in test cohort. Afterwards, Kaplan-Meier curves, univariate and multivariate Cox and subgroup analysis were employed to assess the accuracy of our signature. Immune cell infiltration, checkpoint and the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm were used to investigate the immune environment and immunotherapy of BLCA patients. Furthermore, we confirmed the role of TFRC in bladder cancer cell lines T24 and UMUC-3 through cell experiments. Results A combined hypoxia and immune signature containing 8 genes were successfully established. High-risk group in both training and test cohorts had significantly poorer OS than low-risk group. univariate and multivariate Cox analysis indicated our signature could be regarded as an independent prognostic factor. Different checkpoint was differently expressed between two groups, including CTLA4, HAVCR2, LAG3, PD-L1 and PDCD1. TIDE analysis indicated high-risk patients had poor response to immunotherapy and easier to have immune escape. The drug sensitivity analysis showed high-risk group patients were more potentially sensitive to many drugs. Meanwhile, TFRC could inhibit the proliferation and invasion ability of T24 and UMUC-3 cells. Conclusion A combined hypoxia and immune-related gene could be a novel predictive model for OS and immunotherapy estimation of BLCA patients and TFRC could be used as a potential therapeutic target in the future.

show abstract

“…Immunotherapy is an important for BLCA patients. Thus immune cell in ltration and immune-related genes had gained much research 26,27 . Although many prognostic models have constructed and predicted survival outcomes in BLCA based on hypoxia-related genes or immune-related genes, combing hypoxia-and immune-related genes is a novel method.…”

Section: Discussionmentioning

confidence: 99%

Identification of hypoxia- and immune- based prognostic signature and validation of TFRC as a potential biomarker and therapeutic target in BLCA

Tang,

Wang,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Bladder cancer is a common malignancy of the urinary system, and the survival rate and recurrence rate of patients with muscular aggressive (MIBC) bladder cancer are not ideal. Hypoxia is a pathological process in which cells acquire special characteristics to adapt to anoxic environment, which can directly affect the proliferation, invasion and immune response of bladder cancer cells. Understanding the exact effects of hypoxia and immune-related genes in BLCA is helpful for early assessment of the prognosis of BLCA. However, the prognostic model of BLCA based on hypoxia and immune-related genes has not been reported. Purpose Hypoxia and immune cell have important role in the prognosis of bladder cancer (BLCA). The aim of this study was to investigate whether hypoxia and immune related genes could be a novel tools to predict the overall survival and immunotherapy of BLCA patients. Methods Firstly, we downloaded transcriptomic data and clinical information of BLCA patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. A combined hypoxia and immune signature was then constructed on the basis of the training cohort via least absolute shrinkage and selection operator (LASSO) analysis and validated in test cohort. Afterwards, Kaplan-Meier curves, univariate and multivariate Cox and subgroup analysis were employed to assess the accuracy of our signature. Immune cell infiltration, checkpoint and the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm were used to investigate the immune environment and immunotherapy of BLCA patients. Furthermore, we We confirmed the role of TFRC in bladder cancer cell lines T24 and UMUC-3 through cell experiments. Results A combined hypoxia and immune signature containing 8 genes were successfully established. High-risk group in both training and test cohorts had significantly poorer OS than low-risk group. univariate and multivariate Cox analysis indicated our signature could be regarded as an independent prognostic factor. Different checkpoint was differently expressed between two groups, including CTLA4, HAVCR2, LAG3, PD-L1 and PDCD1. TIDE analysis indicated high-risk patients had poor response to immunotherapy and easier to have immune escape. The drug sensitivity analysis showed high-risk group patients were more potentially sensitive to many drugs. Meanwhile, TFRC could inhibit the proliferation and invasion ability of T24 and UMUC-3 cells. Conclusion A combined hypoxia and immune-related gene could be a novel predictive model for OS and immunotherapy estimation of BLCA patients and TFRC could be used as a potential therapeutic target in the future.

show abstract

m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer

Cited by 29 publications

References 43 publications

A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer

A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer

Identification of hypoxia- and immune- based prognostic signature and validation of TFRC as a potential biomarker and therapeutic target in bladder cancer

Identification of hypoxia- and immune- based prognostic signature and validation of TFRC as a potential biomarker and therapeutic target in BLCA

Contact Info

Product

Resources

About